By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the National Medical Products Administration (NMPA) has accepted its Biologics License Application (BLA) for drotokibart (SHR-1819) in the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is inadequately controlled with topical therapies, or for whom such therapies are not advisable. The acceptance moves the company’s independently developed IL-4Rα monoclonal antibody one step closer to potential approval in one of immunology’s fastest-growing therapeutic categories.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Biologics License Application (BLA) acceptance |
| Product | drotokibart (SHR-1819) |
| Indication | Moderate-to-severe atopic dermatitis in adults inadequately controlled by, or unsuitable for, topical therapies |
| Date | 03 Sept 2026 |
| Next Steps | NMPA technical review leading to potential marketing approval in China |
Drug Profile & Mechanism of Action
- Molecule: drotokibart (SHR-1819), a recombinant humanized monoclonal antibody targeting human IL-4Rα
- Origin: Orthogonally and independently developed by Hengrui Pharmaceuticals
- Mechanism: Dual blockade of both IL-4 and IL-13 signaling pathways — key drivers of Type 2 inflammation
- Therapeutic Scope: Investigational indications span multiple Type 2 inflammatory diseases, including atopic dermatitis, prurigo nodularis, and allergic rhinitis
- Strategic Fit: Anchors Hengrui’s expanding biologics portfolio in dermatology and immunology beyond oncology
Clinical & Development Outlook
- The accepted BLA focuses on moderate-to-severe atopic dermatitis in adults with inadequate response or intolerance to topical therapies — a well-defined, high-need population
- Prurigo nodularis and allergic rhinitis remain in earlier investigational stages, offering multi-indication optionality on a single molecule
- BLA acceptance signals that the submitted data package has met NMPA’s initial completeness standards for formal review
Market Impact & Outlook
- Competitive landscape: An approved IL-4Rα antibody would position Hengrui against established biologic benchmarks in atopic dermatitis, with differentiation driven by clinical profile and domestic commercial reach
- Large addressable market: Atopic dermatitis affects a substantial adult population in China, and biologic penetration remains low relative to developed markets
- Pipeline breadth: The molecule’s Type 2 inflammation platform supports expansion into prurigo nodularis and allergic rhinitis, extending potential lifecycle value
- Portfolio momentum: Reinforces Hengrui’s transition toward innovative biologics as a dual-listed leader in Chinese pharma (SHA: 600276; HKG: 1276)
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding regulatory review timelines, drug approval and commercial potential are forward-looking and subject to risks and uncertainties, including review outcomes, clinical safety and efficacy findings, and competitive dynamics. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech